Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated molecules, including cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development.
Recent Press Releases
February 2, 2023
November 23, 2022
November 9, 2022
Events & Presentations
February 09, 2023 at 3:55 PM EST
December 12, 2022 at 1:00 PM EST
December 01, 2022 at 12:30 PM EST
Data Provided by Refinitiv. Minimum 15 minutes delayed.